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Abstract
Background: Benign prostatic hyperplasia (BPH) is one of the common male diseases, which is provoked by
dihydrotestosterone (DHT) and androgen signals. Several studies showed that curcumin has various effects of
prevention and treatment to diseases. We investigated whether curcumin may repress the development of BPH in male
Wistar rats.
Methods: Seven weeks male Wistar rats were and divided into 4 groups (normal group, BPH group, finasteride group,
curcumin group; n = 8 for each group). In order to induce BPH in rats, rats were castrated and testosterone was injected
subcutaneously everyday (s.c., 20 mg/kg). Rats in the curcumin group were treated 50 mg/kg, administered orally for
4 weeks. After 4 weeks, all rats were sacrificed and their prostate and serum were analyzed.
Results: Compared to the finasteride group as positive group, the curcumin group showed similarly protective effect
on BPH in histopathologic morphology, prostate volume. Results of immunohistochemistry and western-blot showed
decreased expressions of VEGF, TGF-ß1, and IGF1 were also decreased in the curcumin group.
Conclusions: These results suggested that curcumin inhibited the development of BPH and might a useful herbal
treatment or functional food for BPH.
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Background
Benign prostatic hyperplasia (BPH) is a common male
disease causing lower urinary tract distress in aging men
[1]. Several studies suggested that BPH is a multifactorial
disease [2], however, it has known that hormonal factor
contributes to the hyperplastic growth of prostate [1].
Underlying etiology of BPH has not been completely
identified, however, it has been well established that the
prostate gland in the aging men is affected by androgens.
Many researchers reported steroid 5-alpha reductase,
which converts testosterone in serum into dihydrotestos-
terone (DHT) in target tissue, as most important factor
in current BPH treatment [3]. DHT synthesized by ster-
oid 5-alpha reductase increases as aging, hence, prostatic
gland of aged man may be affected more by steroid
5-alpha reductase [4]. Conventional steroid 5-alpha
reductase inhibitors, such as finasteride and dutasteride,
were successful in the treatment of hyperplastic growth of
prostate, however, these drugs were responsible for ad-
verse effects, such as gynecomastia, dizziness, upper
respiratory infections, headache, and chest pain [5, 6].
Such effect may limit the use of conventional drugs
for BPH, however, might be avoided by commonly
used safe agents.
Curcumin is widespread, inexpensive, and highly safe
to human [7]. It is polyphenolic natural compound from
Curcuma longa [8], with diverse drug activities against
aging related events, including dermatologic changes [9],
retinal diseases [10], Parkinson’s disease (PD) [11], renal
antioxidative effect [12], ischemic oxidative damages in
diverse organs [13–15], and cancers [16]. Curcumin ana-
logues may facilitate degradation of androgen receptor
(AR) in prostate cancer [17], and may induce apoptosis
of prostate cancer cell by IkBalpha, c-Jun and androgen
receptor [18]. Curcumin shows suppressive effect on
HIF1a [19, 20], which was suggested as a key molecule
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for transition from prostatitis to BPH [21]. Moreover, it
was proven to be a potent TNF blocker [7], and its anti-
oxidant effect may suppress LOX1 [22]. Administration
of curcumin was investigated as liposomal-formulated
curcumin in Parkinson’s disease (PD) [11], and lecithi-
nized curcumin delivery system in BPH [23].
These previous reports indicate that curcumin may
have protective role in BPH, however, effect of curcumin
on BPH has not been investigated, which is responsible
for the synthesis of DHT, an active metabolite of testos-
terone. Therefore, we investigated whether the curcumin
has protective on testosterone induced BPH rat model.
Methods
Preparation of the curcumin
The chemical structure of curcumin was purchased from
SAMCHUN (#121703 Pyongtack, Korea).
Animals
The animals used in this study were 7 weeks male Wistar
(Central Lab Animal Inc, Korea) with an average body
weight of 250 ± 10 g. The animal room was maintained at
22 ± 2 °C and at 40 ~ 70 % relative humidity. Room light-
ing consisted of 12 h periods of light and dark. All experi-
ments were carried out according to the protocols
approved by the Animal Care Committee of the Animal
Center at Kyung Hee University and in accordance with
guidelines from the Korean National Health Institute of
Health Animal Facility.
Induction of BPH and treatments
After orchiectomy, the rats were divided into four
groups (n = 8). BPH was induced by subcutaneous
injection of testosterone (20 mg/kg) for 4 weeks: (A) a
normal group; (B) BPH that induced testosterone group,
injected subcutaneously; (C) curcumin group that treated
50 mg/kg, administered orally for 4 weeks; (D) finasteride
group that treated 1 mg/kg, administered orally, as a
positive anti-BPH drug and was purchased from
Sigma-Aldrich (St Louis, MO, USA). The dosage of
curcumin (50 mg/kg) referred to previous study [7].
All materials were administered to animals once daily
for 4 weeks, and body weight was measured weekly.
After 4 weeks, all animals were fasted overnight. Blood
was collected in EDTA tubes, placed on ice, serum
immediately was separated and stored at −20 °C. After
animals were sacrificed, fresh prostate was stored in
formaldehyde solution for light microscopic observa-
tion. The rest of the prostate were stored at −70 °C for
the later analysis.
Blood collection and biochemical analysis
At the end of the experiment, the food was removed and
experiments were performed between 9 AM and 12 PM.
Blood samples were obtained in serum separating tube
(SST) from the heart of rat at the end of the experiment.
Blood samples were centrifuged at 3000 × g for 15 min,
at 4 °C and serum was obtained and stored at −70 °C
before analyzed biochemical test. Glucose, total protein,
GOT (glutamic oxaloacetic transaminase), and GPT
(glutamic pyruvic transaminase), were analyzed by Green-
lab (Seoul, Korea).
Histopathological examination
Fixed prostate tissue embedded in paraffin wax was cut
into 5 μm thick sections. Then the tissues were stained
Table 1 Effects of curcumin on body weight in each group
Normal BPH Curcumin Finasteride
Body weight (g)
Initial weight 250 250 250 250
Final weight 362.23 ± 5.72 365.50 ± 6.26 368.34 ± 5.43 367.50 ± 6.75
Total body weight
gains for 30 days
112.23 ± 5.72 115.50 ± 6.26 118.34 ± 5.43 117.50 ± 6.75
Data are presented as mean ± S.E. (n = 8)
Normal, normal group; BPH, testosterone induced BPH group; curcumin, testosterone induced BPH with curcumin (200 mg/ml) group; finasteride, testosterone
induced BPH with finasteride (1 mg/ml) group
Table 2 The effect of curcumin in each group
Normal BPH Curcumin Finasteride
Glucose (mg/dl) 137.00 ± 8.09 115.89 ± 3.48# 153.60 ± 3.18** 128.58 ± 5.79
Total protein (g/dl) 5.72 ± 0.06 5.92 ± 0.06 5.65 ± 0.12 5.85 ± 0.09
AST (GOT) (U/L) 88.86 ± 6.50 97.67 ± 9.69 101.20 ± 6.86 101.43 ± 4.92
ALT (GPT) (U/L) 28.43 ± 1.80 28.12 ± 1.53 36.00 ± 2.22#, * 28.86 ± 0.80
Data are presented as mean ± S.E. (n = 8)
#P < 0.05 compared with normal group; *P < 0.05, **P < 0.01, compared with BPH group
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by Harris’ hematoxylin-eosin according to standard pro-
cedure. The sections were mounted and cover slipped
using mounting solution. Size and thickness of epithelial
cell in ventral lobe of prostate tissue was assessed in
order to identify effect of curcumin on BPH.
Immunohistochemistry
Immunostaining was performed on 4 μm sections after
deparaffinization. Antigen retrieval was performed in cit-
rate buffer pH 6.0 with 95 °C for 10 min prior to perox-
ides quenching with 3 % H2O2 in PBS for 10 min. Then
sections were washed with PBS and preblocked with
normal goat or rabbit serum for 10 min. In the step of
primary antibody reaction, slides were incubated, respect-
ively, with anti-VEGF (Santa Cruz, CA, USA) in a 1:200
dilution, anti-TGF-β1 (Santa Cruz, CA, USA in a 1: 200
dilution, and anti-IGF-1 (Santa Cruz, CA, USA) in a 1: 200
dilution for overnight at 4 °C. Then, the sections were incu-
bated with biotinylated secondary antibodies (1: 1000) for
1 h. Following a washing step with PBS, the streptodavidin-
HRP was applied. Finally, the sections were rinsed in PBS,
developed with diaminobenzidine tetrahydrochloride sub-
strate (DAB) in 10 min. At least three random region of
each section were examined at × 100 and × 400.
Western-blot
Prostate tissues were homogenized by a tissue homogenizer
in protein lysis buffer. After centrifuge at 12,000 rpm,
protein was extracted and protein concentration was
determined using Bradford protein assay. Proteins were
transferred membranes and membranes were incubated
with the antibodies used for western-blot analysis were
anti-VEGF (Santa Cruz, CA, USA) in a 1:200 dilution,
anti-TGF-β1 (Santa Cruz, CA, USA in a 1 : 200 dilu-
tion, and anti-IGF-1 (Santa Cruz, CA, USA) for over-
night. Then, HRP-conjugated secondary antibody
(1:5000, Pierce Chemical) for 1 h at room temperature
(RT) and membrane was developed with ECL western
blotting detection reagents (GE Healthcare Biosciences,
Pittsburgh, PA, USA).
Table 3 Prostate weight, prostate volume, and prostate weight ratio in each group
Normal BPH Curcumin Finasteride
Prostate weight (g) 1.04 ± 0.04 1.36 ± 0.03 ### 0.91 ± 0.05 *** 0.73 ± 0.03 ***
Prostate volume (cm3) 1.13 ± 0.12 1.73 ± 0.19 ### 0.67 ± 0.06 *** 0.86 ± 0.08 ***
Prostate weight ratio (mg/100 g of BW) 0.28 ± 0.02 0.40 ± 0.03 ### 0.22 ± 0.02 *** 0.27 ± 0.02 ***
Data are presented as mean ± S.E. (n = 8)
###P < 0.001 compared with the normal group; ***P < 0.001 compared with the BPH group
Fig. 1 H&E stains of prostate tissue in each group (× 100 and × 400). Arrowheads indicate interacina fibrosis in ventral lobe of prostate tissue.
# P < 0.05 compared with the normal group; * P < 0.05 compared with the BPH group
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Statistical analyses
All of the values showed as the mean ± S.E. Significant
difference among the groups was statistically performed
using a one-way analysis of variances (ANOVA), followed
by a non-parametric post Tukey test. All p values are two-
tailed, and significance was set at p < 0.05. All statistical
analysis was performed using the SPSS for windows,
version 21.0 (SPSS Inc.).
Results
Measurement of weight change
Body weight change shows in Table 1. Final body weight
was measured after 4 weeks. The final body weight in
normal, BPH, curcumin, and finasteride groups was
increased compared with initial body weight (normal
group, 69. 06 %, BPH group, 68.49 %, curcumin group,
67.93 %, and finasteride group 68.12 %, respectively).
The differences among each groups did not show signifi-
cant difference (p > 0.05).
Glucose, total protein, AST, and ALT level in serum level
The BPH group demonstrated decrease glucose level in
serum than the normal group (Table 2). Curcumin treat-
ment group showed effect on plasma glucose. AST level
in serum did not significantly different among groups.
However, ALT level in curcumin group showed higher
than other groups. And, total protein level in serum in
the BPH group was slightly increased, compared with
the normal group. However, differences among the
groups were not statically significant (p > 0.05). The total
protein of curcumin group showed decrease compared
with that of the normal group.
Prostate ratio according to volume and weight of the
prostate
Prostate weight, volume, and weight ratio show in Table 3.
Prostate weight of the BPH group (1.36 ± 0.03 g,
mean ± S.E.) was significantly increased compared
Fig. 2 The expressions of vascular endothelial growth factor A(VEGF), transforming growth factor, beta 1(TGF-ß1), and insulin-like growth factor
1(IGF1) by immunohistochemistry in each group (× 100). # P < 0.05 compared with the normal group; * P < 0.05 compared with the BPH group
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with that of the normal group (1.04 ± 0.04 g), and the
administration groups of curcumin and finasteride
treatment group were significantly decreased than that
of the BPH group, 0.91 ± 0.05 g and 0.73 ± 0.03 g,
respectively. The prostate volume of BPH group (1.73
± 0.19 cm3) was significantly higher than that of nor-
mal group (1.13 ± 0.12 cm3), and the administration
groups of curcumin and finasteride group were sig-
nificantly lower than that of BPH group, 0.67 ±
0.06 cm3 and 0.86 ± 0.08 cm3, respectively. Finally,
prostate weight ratio of the BPH group (0.40 ±
0.03 mg/100 g of BW) was significantly higher than
that of the normal group 0.28 ± 0.02 mg/100 g of BW),
and the administration groups of curcumin group and
finasteride group were significantly lower than that of the
BPH group, 0.22 ± 0.02 mg/100 g of BW and 0.27 ±
0.02 mg/100 g of BW, respectively.
Histological morphology of the prostate
In order to examine the effects of the administration of
curcumin on histological morphology of prostate tissue,
H&E staining was performed. Prostate of rats generally
consists of three distinct including dorsal lobe, lateral
lobe, and ventral lobe. We analyzed ventral lobe of
prostate tissue. As shown in Fig. 1, the histological
morphology of the prostate tissue in the BPH group
was abnormal. The connective tissue in prostate was
increased oval shape and size. The epithelial cell layer
and lumen space in the BPH group were increased than
those of the normal group. And there was interacinar
fibrosis in ventral lobe of rats in the BPH group. The
decreases in hyperplasia and the epithelial layer thick-
ness were observed in the curcumin group and the
finasteride group as positive group compared with
those of the BPH group (p < 0.05).
Expression of VEGF, TGF-ß1, and IGF1 of prostate tissue
In order to examine the effects of the administration of
curcumin on expression of growth factors in prostate
tissue, IHC and western-blot were performed. As shown
in Figs 2 and 3, the protein expressions of growth factors
(VEGF, TGF-ß1, and IGF1) in the BPH group were
increased than those of the normal group (p < 0.05).
These proteins expressions of VEGF, TGF-ß1, and IGF1
both curcumin group and finasteride group showed
decrease compared with those of the BPH group (p < 0.05).
Discussion
In previous researches, blockade of steroid 5-alpha
reductase was associated with inhibition of development
of BPH [1]. Previous evidences for inhibition effect on
BPH development in rats were found by reduction of
Fig. 3 The expressions of vascular endothelial growth factor A(VEGF), transforming growth factor, beta 1(TGF-ß1), and insulin-like growth factor
1(IGF1) by western-blot in each group. # P < 0.05 compared with the normal group; * P < 0.05 compared with the BPH group
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prostate size or decreased histopahthologic morphology
of BPH [21, 24].
Prostate require high levels of steroid androgens even
for the maintenance of tissue architecture and AR [25].
Testosterone and DHT may influence cell signals by AR,
which is nuclear sex steroid hormone receptor, and plays
a role in activation of growth factors [4, 26]. Such role in
the prostate has permissive effect in transformation from
normal prostate to BPH or prostatic cancer [27–29].
Whether which of AR-activated growth factors may
affect BPH development may be ambiguous, however,
there were some previous evidences that decreased
expressions of VEGF, TGF-ß1 [30, 31], and IGF1 [32, 33]
were associated with inhibition of hyperplastic growth of
prostate [29]. VEGF may be associated with angiogenic
growth in hyperplasia [34]. Stromal extracellular matrix
(ECM) accumulation is implicated in hyperplastic
growth of BPH [26, 35, 36], and TGF-ß1 may affect the
process of ECM deposition and inflammatory signals
[37]. And last, IGF signaling was indicated to be respon-
sible for the prostatic enlargement [38] and LUTS with
obesity and diabetes [33].
It has been also known that such factors may be inhib-
ited by curcumin. Curcumin may inhibit mitogenic effect
of IGF1 and IGF1R signals in hypertrophic cells [39, 40].
Moreover, it may regulate various molecular targets in-
cluding EGF, PDGF, VEGF, NF-kB, and STAT3 in cancers
[41]. Regulation of VEGF by curcumin is seen in age-
related macular degeneration model of mouse [42]. TGF-
beta responses induced by cellular damages [43] and T
cell-dependent inflammatory stress [44] may be reduced
by curcumin. And chronic immune-mediated stress may
be ameliorated by curcumin [45, 46]. These previous re-
ports suggest that curcumin may have some beneficial ef-
fects on aging-related changes of various body organs,
including prostate [18].
In the present study, curcumin showed positive ef-
fect of morphology in prostate ratio and histopath-
ology in BPH rat model. Moreover, curcumin showed
decreased expression of VEGF, TGF-ß1, and IGF1
when compared to testosterone induced BPH group.
Our result is in concordance with previous reports
that curcumin inhibited the expression of the growth
factors, and that curcumin may inhibit androgen ef-
fect on prostate.
Conclusion
In summary, curcumin significantly lower prostate weight
and prostate volume. And curcumin treatment decreased
expressions VEGF, TGF-ß1, and IGF1 among growth
factors in prostate tissue.
These findings suggested that curcumin inhibited
the development of BPH and might by a useful
herbal treatment.
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